NO20082092L - Pyrazolopyrimidiner som proteinkinaseinhibitorer - Google Patents

Pyrazolopyrimidiner som proteinkinaseinhibitorer

Info

Publication number
NO20082092L
NO20082092L NO20082092A NO20082092A NO20082092L NO 20082092 L NO20082092 L NO 20082092L NO 20082092 A NO20082092 A NO 20082092A NO 20082092 A NO20082092 A NO 20082092A NO 20082092 L NO20082092 L NO 20082092L
Authority
NO
Norway
Prior art keywords
compounds
pyrazolopyrimidines
protein kinase
kinase inhibitors
protein
Prior art date
Application number
NO20082092A
Other languages
English (en)
Inventor
Timothy J Guzi
Kamil Paruch
Carmen S Alvarez
Michael P Dwyer
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20082092L publication Critical patent/NO20082092L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

I dens mange utførelsesformer tilveiebringer den foreliggende oppfinnelse en ny klasse av aminosubstituerte pyrazolo[1, 5-a]pyrimidinforbindelser representert ved strukturformel (I) som inhibitorer av protein- og/eller sjekkpunktkinaser, fremgangsmåter for fremstilling av slike forbindelser, farmasøytiske preparater som omfatter én eller flere slike forbindelser, fremgangsmåter for fremstilling av farmasøytiske preparater som omfatter én eller flere slike forbindelser, og fremgangsmåter for behandling, forebyggelse, inhibering eller lindring av én eller flere sykdommer forbundet med protein- eller sjekkpunktkinasene, ved å anvende slike forbindelser eller farmasøytiske preparater.
NO20082092A 2005-10-06 2008-05-05 Pyrazolopyrimidiner som proteinkinaseinhibitorer NO20082092L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72419705P 2005-10-06 2005-10-06
PCT/US2006/039136 WO2007041712A1 (en) 2005-10-06 2006-10-04 Pyrazolopyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20082092L true NO20082092L (no) 2008-07-04

Family

ID=37560916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082092A NO20082092L (no) 2005-10-06 2008-05-05 Pyrazolopyrimidiner som proteinkinaseinhibitorer

Country Status (18)

Country Link
US (1) US7776865B2 (no)
EP (1) EP1931676B1 (no)
JP (2) JP5052518B2 (no)
KR (1) KR20080063806A (no)
CN (1) CN101321760A (no)
AR (1) AR056206A1 (no)
AT (1) ATE533770T1 (no)
AU (1) AU2006299338A1 (no)
BR (1) BRPI0617150A2 (no)
CA (1) CA2624882C (no)
EC (1) ECSP088350A (no)
IL (1) IL190598A0 (no)
NO (1) NO20082092L (no)
PE (1) PE20070543A1 (no)
RU (1) RU2008117298A (no)
TW (1) TW200745123A (no)
WO (1) WO2007041712A1 (no)
ZA (1) ZA200802995B (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931676B1 (en) * 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
AU2007223865A1 (en) * 2006-03-08 2007-09-13 Novartis Ag Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
BRPI0712016A2 (pt) * 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
EP2089391B1 (en) * 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
EP2150553B1 (en) * 2007-05-09 2011-10-05 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US8603998B2 (en) * 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
ES2462642T3 (es) * 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
KR20110011669A (ko) * 2008-05-12 2011-02-08 엠네스틱스, 인코포레이티드 Ｒｈｏ 키나제를 억제하고 학습 및 기억력을 개선하기 위한 화합물
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
AU2010213192A1 (en) * 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
BR112012013349B1 (pt) * 2009-12-01 2019-10-22 Abbott Lab compostos tricíclicos
JP2013530250A (ja) * 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
CN103384670B (zh) * 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
CN104066736B (zh) * 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
DK2941432T3 (en) 2012-12-07 2018-06-14 Vertex Pharma 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512816A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
TW201536293A (zh) 2013-07-18 2015-10-01 Taiho Pharmaceutical Co Ltd 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥
PL3023100T3 (pl) * 2013-07-18 2019-07-31 Taiho Pharmaceutical Co., Ltd. Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG11201610197XA (en) 2014-06-05 2017-01-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
RS59054B1 (sr) 2014-06-17 2019-08-30 Vertex Pharma Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
ES2812785T3 (es) 2015-03-31 2021-03-18 Taiho Pharmaceutical Co Ltd Cristal de compuesto de alquinilo de benceno 3,5-disustituido
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
RU2769696C2 (ru) * 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
BR112020001714A2 (pt) 2017-07-28 2020-07-21 Nimbus Lakshmi, Inc. inibidores de tyk2 e usos dos mesmos
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
FI3769765T3 (fi) 2018-03-19 2024-05-15 Taiho Pharmaceutical Co Ltd Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
AU2020221247A1 (en) 2019-02-12 2021-08-05 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
US5688949A (en) 1991-04-22 1997-11-18 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2002508324A (ja) 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
WO2000042042A2 (en) 1999-01-11 2000-07-20 Princeton University High affinity inhibitors for target validation and uses thereof
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
EP1303513A1 (en) 2000-07-26 2003-04-23 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
ZA200301696B (en) 2000-09-15 2004-04-28 Vertex Pharma Isoxazoles and their use as inhibitors of erk.
US7067520B2 (en) * 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2002212076A (ja) * 2000-11-17 2002-07-31 Ishihara Sangyo Kaisha Ltd 縮合複素環化合物またはその塩を含有する糖尿病の予防または治療薬
AU2002225096B8 (en) 2000-12-20 2006-07-27 Ipsen Pharma S.A.S. Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
MXPA04012245A (es) 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
NZ539165A (en) * 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
AU2006206573B9 (en) * 2005-01-19 2011-09-29 Merck Sharp & Dohme Corp. Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1931676B1 (en) * 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2624882C (en) 2014-05-20
CA2624882A1 (en) 2007-04-12
JP5052518B2 (ja) 2012-10-17
AR056206A1 (es) 2007-09-26
CN101321760A (zh) 2008-12-10
ECSP088350A (es) 2008-05-30
US7776865B2 (en) 2010-08-17
ATE533770T1 (de) 2011-12-15
KR20080063806A (ko) 2008-07-07
EP1931676A1 (en) 2008-06-18
BRPI0617150A2 (pt) 2011-07-12
EP1931676B1 (en) 2011-11-16
JP2009511491A (ja) 2009-03-19
RU2008117298A (ru) 2009-11-20
AU2006299338A1 (en) 2007-04-12
IL190598A0 (en) 2008-11-03
US20070083044A1 (en) 2007-04-12
PE20070543A1 (es) 2007-06-14
ZA200802995B (en) 2009-02-25
TW200745123A (en) 2007-12-16
WO2007041712A1 (en) 2007-04-12
JP2012082233A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
NO20082092L (no) Pyrazolopyrimidiner som proteinkinaseinhibitorer
NO20082091L (no) Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
NO20064046L (no) Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer
NO20082530L (no) Imidazopyraziner som proteinkinaseinhibitorer
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20092668L (no) 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20055092L (no) Substituerte pyrimidioner
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2007056164A3 (en) Aminopyrimidines useful as kinase inhibitors
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20082093L (no) Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008045268A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007022384A3 (en) Pyrazine kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application